← All trials
NCT06610682
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2024
- Primary completion
- Dec 31, 2026
- Completion date
- May 15, 2027
- First posted
- Sep 24, 2024
- Last posted
- Sep 24, 2024
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Johns Hopkins UniversityLead sponsor
- Novellus TherapeuticsCollaborator
- Johns Hopkins UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.